

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]

Al-Janabi A, Yiu ZZN. *Psoriasis (Auckl)*. 2022;12:1–14.

The authors have advised that there is an error in Table 1 on page 2. The text “IL-7A” in the Target column for the Ixekizumab row should read “IL-17A”.

The authors apologize for this error.

Publish your work in this journal

Psoriasis: Targets and Therapy is international, peer-reviewed, open access journal focusing on psoriasis, nail psoriasis, psoriatic arthritis and related conditions, identification of therapeutic targets and the optimal use of integrated treatment interventions to achieve improved outcomes and quality of life. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/psoriasis-targets-and-therapy-journal>

<https://doi.org/10.2147/PTT.S380486>